| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca32fd2a44fd326ffd027a75a57bd13f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4703 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56988
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-569 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 |
| filingDate |
2009-09-11^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6daf050a163e5b6591ce34df2a18f03f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_480588d6a1e665cde6b0bab494f0869c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d64026a278b12bc709e026e1bc72a0ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae3f81d3aae7c424272761c894c69681
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3254337f74ff44a333b5f60139f284fb |
| publicationDate |
2011-09-22^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011229474-A1 |
| titleOfInvention |
Monitoring and inhibiting human immunodeficiency virus infection by modulating hmgb1 dependent triggering of hiv-1 replication and persistence |
| abstract |
Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8906634-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016018418-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9766254-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10012655-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9164107-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9164103-B2 |
| priorityDate |
2008-09-11^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |